Clinical and patient reported outcomes in multiple sclerosis patients on disease modifying therapies

被引：0
|
作者：
Fernandes, L. [1 ]
Horton, M. [2 ]
Russell, M. [1 ]
Lily, O. [1 ]
Ford, H. L. [1 ]
机构：
[1] Leeds Teaching Hosp NHS Trust, Leeds Ctr Neurosci, Leeds, W Yorkshire, England
[2] Univ Leeds, Leeds, W Yorkshire, England
来源：
MULTIPLE SCLEROSIS JOURNAL | 2019年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P812
引用
收藏
页码：417 / 418
页数：2
相关论文
共 50 条
  • [41] Switching disease modifying therapies in multiple sclerosis patients: a study on 110 patients
    Morra, VB
    Coppola, G
    Vacca, G
    Longobardi, M
    Ascione, S
    Schiavone, V
    Pagano, A
    Bonavita, V
    Orefice, G
    JOURNAL OF NEUROLOGY, 2004, 251 : 88 - 88
  • [42] Association between disease-modifying therapies and adverse clinical outcomes in multiple sclerosis patients with COVID-19 infection
    Maghbooli, Z.
    Aghababaei, Y.
    Hosseinpour, H.
    Fatahi, M.
    Varzandi, T.
    Hamtaee, S.
    Mohammad-Nabi, S.
    Eskandarieh, S.
    Aghighi, M.
    Moghadasi, A. Naser
    Sahraian, M.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 76 - 77
  • [43] The immunogenicity of disease-modifying therapies for multiple sclerosis: Clinical implications for neurologists
    Fox, Edward J.
    Vartanian, Timothy K.
    Zamvil, Scott S.
    NEUROLOGIST, 2007, 13 (06) : 355 - 362
  • [44] Changes in patient-reported outcomes between continuers and discontinuers of disease modifying therapy in patients with multiple sclerosis over age 60
    Hua, Le H.
    Harris, Haleigh
    Conway, Devon
    Thompson, Nicolas R.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 30 : 252 - 256
  • [45] Adherence to Disease-Modifying Therapies for Multiple Sclerosis
    Higuera, Lucas
    Carlin, Caroline S.
    Anderson, Sarah
    Journal of Managed Care & Specialty Pharmacy, 2016, 22 (12): : 1394 - 1401
  • [46] Immunosenescence and the risk of disease modifying therapies in Multiple Sclerosis
    Mehling, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 39 - 39
  • [47] Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice
    Lanzillo, R.
    Bonavita, S.
    Quarantelli, M.
    Vacca, G.
    Lus, G.
    Amato, L.
    Carotenuto, A.
    Tedeschi, G.
    Orefice, G.
    Morra, V. Brescia
    NEUROLOGICAL SCIENCES, 2013, 34 (04) : 521 - 528
  • [48] Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice
    R. Lanzillo
    S. Bonavita
    M. Quarantelli
    G. Vacca
    G. Lus
    L. Amato
    A. Carotenuto
    G. Tedeschi
    G. Orefice
    V. Brescia Morra
    Neurological Sciences, 2013, 34 : 521 - 528
  • [49] Oral Disease-Modifying Therapies for Multiple Sclerosis
    Kim, Woojun
    Zandona, Manuella Edler
    Kim, Su-Hyun
    Kim, Ho Jin
    JOURNAL OF CLINICAL NEUROLOGY, 2015, 11 (01): : 9 - 19
  • [50] Multiple Sclerosis, Disease-Modifying Therapies, and Infections
    Langer-Gould, Annette M.
    Smith, Jessica B.
    Gonzales, Edlin G.
    Piehl, Fredrik
    Li, Bonnie H.
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2023, 10 (06):
12345